Therapeutic efficacy of a potent anti-VEEV antibody is contingent on humoral and cell-mediated cytotoxic immunity.
Abstract not provided.
Schwedler, Jennifer↗
Engineering topics
Thatcher, Christine
Publications and source records attributed to Thatcher, Christine.
Characterization of SNL identified BBB-penetrating moieties (BBB PMs) for delivery of therapeutic cargo to the CNS.
Abstract not provided.
Sumner, Christopher↗
Nanoparticle Mediated Delivery of Therapeutic mRNA for Protection Against Lung Damage
Medical countermeasures (MCMs) based on messenger ribonucleic acid (mRNA) are promising due to their programmability, targeting precision and specificity, predictable physicochemical properties, and amenability to scalable manufacture. However, safe and effective delivery vehicles are needed, especially for targeting the lung. We developed a generalized approach to nanoparticle-mediated mRNA delivery to lung, and used it to evaluate candidate therapies. In initial studies, reporter mRNA was delivered using lipid-coated mesoporous silica nanoparticles (LC-MSNs) and lipid nanoparticles (LNPs), the latter with greater consistency. Then, mRNA encoding known protein therapies were delivered using LNPs. These formulations showed some toxicity in mice with lung damage, but those with IL-1RA, sACE2-Ig, and ANGPT1 mRNA were modestly therapeutic on balance. Our work advances the state of the art for mRNA delivery to lung, and provides a foundation for evaluating and characterizing mRNA-based lung therapies, including three that appear to be exceptionally promising.
59 BASIC BIOLOGICAL SCIENCES↗
A targeted opsonization platform for programming innate immunity against rapidly evolving novel viruses.
Recent work has shown that artificial opsonins stimulate the targeted destruction of bacteria by phagocyte immune cells. Artificial opsonization has the potential to direct the innate immune system to target novel antigens, potentially even viral pathogens. Furthermore, the engagement of innate immunity presents a potential solution for the spread of pandemics in a scenario when a vaccine is unavailable or ineffective. Funded by the LDRD late start bioscience pandemic response program, we tested whether artificial opsonins can be developed to target viral pathogens using phage MS2 and a SARS-CoV-2 surrogate. To direct opsonization against these viruses we purified antibody derived viral targeting motifs and attempted the same chemical conjugation strategies that produced bacterial targeting artificial opsonins. However, the viral targeting motifs proved challenging to conjugate using these methods, frequently resulting in precipitation and loss of product. Future studies may be successful with this approach if a smaller and more soluble viral-targeting peptide could be used.
60 APPLIED LIFE SCIENCES↗